Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons

被引：10

作者：

Daniels L.B. ^{[1
]}

机构：

[1] Division of Cardiology, University of California, San Diego, La Jolla, CA, 92037-1300, MC 0986, 9350 Campus Point Drive

来源：

Current Cardiovascular Risk Reports | 2010年 / 4卷 / 2期

关键词：

Natriuretic peptides; Primary prevention; Risk assessment; Screening;

D O I：

10.1007/s12170-010-0078-8

中图分类号：

学科分类号：

摘要：

Current tools for cardiovascular disease (CVD) risk assessment in asymptomatic individuals are imperfect. Preventive measures aimed only at individuals deemed high risk by current algorithms neglect large numbers of low-risk and intermediate-risk individuals who are destined to develop CVD and who would benefit from early and aggressive treatment. Natriuretic peptides have the potential both to identify individuals at risk for future cardiovascular events and to help detect subclinical CVD. Choosing the appropriate subpopulation to target for natriuretic peptide testing will help maximize the performance and the cost effectiveness. The combined use of multiple risk markers, including biomarkers, genetic testing, and imaging or other noninvasive measures of risk, offers promise for further refining risk assessment algorithms. Recent studies have highlighted the utility of natriuretic peptides for preoperative risk stratification; however, cost effectiveness and outcomes studies are needed to affirm this and other uses of natriuretic peptides for cardiovascular risk assessment in asymptomatic individuals. © 2010 The Author(s).

引用

页码：120 / 127

页数：7

共 65 条

[1] Pearson T.A., Blair S.N., Daniels S.R., Et al., AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases, Circulation, 106, pp. 388-391, (2002)
[2] Mosca L., Banka C.L., Benjamin E.J., Et al., Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update, J Am Coll Cardiol, 49, pp. 1230-1250, (2007)
[3] Vasan R.S., Sullivan L.M., Wilson P.W., Et al., Relative importance of borderline and elevated levels of coronary heart disease risk factors, Ann Intern Med, 142, pp. 393-402, (2005)
[4] Greenland P., Knoll M.D., Stamler J., Et al., Major risk factors as antecedents of fatal and nonfatal coronary heart disease events, Jama, 290, pp. 891-897, (2003)
[5] Magnus P., Beaglehole R., The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth, Arch Intern Med, 161, pp. 2657-2660, (2001)
[6] Khot U.N., Khot M.B., Bajzer C.T., Et al., Prevalence of conventional risk factors in patients with coronary heart disease, Jama, 290, pp. 898-904, (2003)
[7] Daniels L.B., Maisel A.S., Natriuretic peptides, J Am Coll Cardiol, 50, pp. 2357-2368, (2007)
[8] Wang T.J., Larson M.G., Levy D., Et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N Engl J Med, 350, pp. 655-663, (2004)
[9] Daniels L.B., Laughlin G.A., Clopton P., Et al., Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study, J Am Coll Cardiol, 52, pp. 450-459, (2008)
[10] Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, pp. 1421-3143, (2002)

← 1 2 3 4 5 6 7 →